With Novartis deal, Adimab expects profitability this year

Lebanon, NH-based Adimab has inked a research collaboration with Novartis, marking its fifth deal with a major pharma company in just over a year. The developer will use its discovery platform to identify fully human antibodies against two targets selected by Novartis. Novartis has rights to commercialize the identified antibodies, while Adimab gets an undisclosed upfront payment, preclinical milestones and licensing fees. Adimab could also receive clinical development milestones...